NIOX GroupCSSPF 77 Debt-to-Equity is 0.02 as of Dec. 2025, which is at its 10-year median of 0.02. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.12 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 705 Medical Devices & Instruments companies, NIOX Group ranks better than 92.48% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for NIOX Group's Debt-to-Equity or its related term are showing as below:
CSSPF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.02 Max: 1.32
Current: 0.02
During the past 13 years, the highest Debt-to-Equity Ratio of NIOX Group was 1.32. The lowest was 0.01. And the median was 0.02.
CSSPF's Debt-to-Equity is ranked better than 92.48% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs CSSPF: 0.02
NIOX Group (OTCPK:CSSPF) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
NIOX Group Debt-to-Equity Related Terms
NIOX Group Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for NIOX Group's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, NIOX Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where NIOX Group's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NIOX Group (CSSPF) has a Debt-to-Equity of 0.02 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on NIOX Group and its competitors. This is near median its historical median of 0.02. Over the past decade, NIOX Group's Debt-to-Equity has ranged from 0.01 to 1.32. According to the industry distribution chart, NIOX Group ranks #53 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 7.5%.
Is NIOX Group's Debt-to-Equity too high?
NIOX Group's current Debt-to-Equity of 0.02 is near median its 10-year median of 0.02. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 1.32. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. NIOX Group's value of 0.02 is 91.3% below this industry median. Based on the distribution chart, NIOX Group ranks #53 out of 705 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #53 out of 705 companies for Debt-to-Equity. This places NIOX Group in the top 8% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.23. NIOX Group's value of 0.02 is 91.3% below this benchmark. Historically, NIOX Group's own Debt-to-Equity has ranged from 0.01 to 1.32 over the past decade. While the company's 10-year median is 0.02 vs. the industry median of 0.23, NIOX Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current Debt-to-Equity of 0.02 is 91.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current Debt-to-Equity is 0.02, which is near median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.12, compared to a current price of $0.75 — trading 33% below its estimated fair value. The current Debt-to-Equity is 0.02, which is near median its 10-year median of 0.02 and 91.3% below the Medical Devices & Instruments industry median of 0.23. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For NIOX Group (CSSPF), the current Debt-to-Equity is 0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.75 is trading 33% below its estimated GF Value™ of $1.12.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
Debt-to-Equity: 0.02 (near median its 10-year median of 0.02)
GF Value™: $1.12 vs. price of $0.75 (33% below fair value)
Industry Position: 91.3% below the Medical Devices & Instruments median (#53 of 705)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
